Biosimilars LatAm – Brazil 2025
As a platform for advancing access to biosimilars in Brazil, this forum convenes senior executives and key stakeholders from the pharmaceutical and regulatory sectors to examine strategies for consolidating Brazil’s leadership in the global biosimilars market. Through engaging panels, expert presentations, and networking sessions, the event explores the role of international alliances, the contributions of ANVISA and academic institutions, and solutions for overcoming regulatory and market challenges to ensure global distribution.
Key Objectives:
– Analyze how alliances with international entities facilitate entry into new markets.
– Discuss the role of ANVISA and universities in fostering research and developing bioprocess talent.
– Address strategies for navigating regulatory and market challenges to enable global distribution of biosimilars.
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Plan Your 1-to-1 Meetings with JackLeckerman App
Speaker Board 2024
Suryanarayana Nagendra
LatAm Cluster Head
Ana Maria Moro
Lab Director
Andre Luiz Jochen
Regulatory Affairs and Quality Director
Marco Antonio Fernandes
Business Development Manager
Carla Juliani
Technical Services Manager Latam
Paulo Fernandes
Consultant - Clinical Development
German Wassermann
Biotechnology Director - R&D
Fatima Ventura
Drug Evaluation Department - Scientific Evaluation Unit
Mariana de Cerqueira
Upstream and Cell Culture Sales Specialist
Alexander Schäfer
Business Development Manager
Juan Amor
Technical Application Specialist (Purification)
Justin Sweeley
Integrated Solutions Sales Manager, North America West
Liana Dalolli
Biopharma Business Unit Director
Cristiano Gonçalves
Director of Innovation and Tech Licensing
Fernando de Rezende Francisco
Executive Manager
Ricardo Campello
Partner
Uilberson Silva
RD&I Director
Marcela Amaral Pontes
Access Manager
Perla Villani Borges
Business Development Manager
Francisco Javier Domingo
Business Unit Director Spain
Anderson Montai
Manager, Specialist in Health Regulation and Surveillance
Flavio Spegiorin Ramos
Partner
Philippe Lauwers
Technology Development Director
Program at a Glance
Understanding INN Suffixes for New Antibodies
This session will clarify the purpose and structure of International Nonproprietary Name (INN) suffixes in the naming of new antibodies, highlighting their role in pharmacovigilance, product differentiation, and regulatory compliance across global markets.
Market Penetration of Biosimilars in Latin America
This session will present key data and trends illustrating the current level of biosimilar adoption across Latin American markets, highlighting growth rates, regulatory advancements, therapeutic areas, and country-specific penetration levels to support strategic decision-making and market expansion planning.
Aligning Brazilian Compliance with EMA Standards for European Market Access
Explore strategies for aligning Brazilian biosimilars with EMA regulatory standards.
Strategic Alliances for Brazilian Biosimilars’ Global Expansio
Analyze how alliances with foreign entities facilitate entry into new markets.
Regulatory Synergy in Brazil’s Biosimilars Landscape
This panel will explore how Brazil can develop a sustainable biosimilars ecosystem by combining local innovation, international regulatory compliance (EMA/FDA), and strategic global partnerships.
Regulatory Synergy in Brazil’s Biosimilars Landscape
Highlighting how innovation in R&D, combined with streamlined regulatory pathways, can accelerate biosimilar development and market entry within Brazil.
Full Programme in the PDF Agenda
Download Agenda
Sponsors
Photo Gallery from Previous Events
Testimonials
-
”What you and your team are doing to advance the biosimilars industry is nothing short of inspiring. The dedication, vision, and passion that drive your work not only create a platform for meaningful discussions but also pave the way for real-world solutions that can positively impact countless lives around the globe. I deeply admire the effort and commitment you all bring to making this a space for innovation and collaboration.”
Srinivas Komala, Country Manager at MSN Labs, Brazil
-
”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”
Alison Bascou, Sr. Regulatory Director at BD, France
-
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."
Jaime Uribe, CEO At PROBIOMED
-
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”
Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
-
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”
Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
-
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”
Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico